MA45574A - Procédés de traitement de lésions ou de pathologies liées à un dème du snc - Google Patents

Procédés de traitement de lésions ou de pathologies liées à un dème du snc

Info

Publication number
MA45574A
MA45574A MA045574A MA45574A MA45574A MA 45574 A MA45574 A MA 45574A MA 045574 A MA045574 A MA 045574A MA 45574 A MA45574 A MA 45574A MA 45574 A MA45574 A MA 45574A
Authority
MA
Morocco
Prior art keywords
ema
injuries
cns
procedures
treatment
Prior art date
Application number
MA045574A
Other languages
English (en)
French (fr)
Inventor
Sven Martin Jacobson
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of MA45574A publication Critical patent/MA45574A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA045574A 2015-10-07 2016-10-07 Procédés de traitement de lésions ou de pathologies liées à un dème du snc MA45574A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07

Publications (1)

Publication Number Publication Date
MA45574A true MA45574A (fr) 2019-05-15

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045574A MA45574A (fr) 2015-10-07 2016-10-07 Procédés de traitement de lésions ou de pathologies liées à un dème du snc

Country Status (15)

Country Link
US (4) US20180280325A1 (cg-RX-API-DMAC7.html)
EP (1) EP3359162B1 (cg-RX-API-DMAC7.html)
JP (5) JP7349786B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240105519A (cg-RX-API-DMAC7.html)
CN (2) CN108348534A (cg-RX-API-DMAC7.html)
AU (3) AU2016335767B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018006925A2 (cg-RX-API-DMAC7.html)
CA (1) CA3001321A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890893A1 (cg-RX-API-DMAC7.html)
ES (1) ES2940669T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257542A1 (cg-RX-API-DMAC7.html)
IL (1) IL258509B2 (cg-RX-API-DMAC7.html)
MA (1) MA45574A (cg-RX-API-DMAC7.html)
MX (1) MX392466B (cg-RX-API-DMAC7.html)
WO (1) WO2017062765A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
JP2022531312A (ja) * 2019-05-02 2022-07-06 バイオジェン チェサピーク エルエルシー 中枢神経系挫傷に苦しむ対象の治療方法
CN120004770A (zh) * 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251388B1 (en) * 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
ES2807274T3 (es) * 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
CA3123813C (en) * 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
CA2806069C (en) * 2010-07-19 2021-01-19 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs
KR20240105519A (ko) 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법

Also Published As

Publication number Publication date
BR112018006925A2 (pt) 2018-10-16
IL258509B2 (en) 2023-04-01
US20180280325A1 (en) 2018-10-04
KR20240105519A (ko) 2024-07-05
CN108348534A (zh) 2018-07-31
AU2025202620A1 (en) 2025-05-01
US20250017880A1 (en) 2025-01-16
JP7592768B2 (ja) 2024-12-02
JP7810762B2 (ja) 2026-02-03
ES2940669T3 (es) 2023-05-10
HK1257542A1 (zh) 2019-10-25
CA3001321A1 (en) 2017-04-13
JP2026069546A (ja) 2026-04-23
US11951085B2 (en) 2024-04-09
MX392466B (es) 2025-03-24
KR20180063296A (ko) 2018-06-11
AU2016335767A8 (en) 2018-06-28
EP3359162A4 (en) 2019-08-28
KR102681027B1 (ko) 2024-07-02
JP2018530564A (ja) 2018-10-18
AU2022279369B2 (en) 2025-02-13
US20240216309A1 (en) 2024-07-04
IL258509B (en) 2022-12-01
JP2021073317A (ja) 2021-05-13
CN115737816A (zh) 2023-03-07
US20220125750A1 (en) 2022-04-28
EP3359162B1 (en) 2022-12-21
AU2022279369A1 (en) 2023-01-19
JP2024164167A (ja) 2024-11-26
AU2016335767B2 (en) 2022-10-06
KR20260093449A (ko) 2026-06-19
JP7349786B2 (ja) 2023-09-25
JP2023053274A (ja) 2023-04-12
WO2017062765A1 (en) 2017-04-13
EA201890893A1 (ru) 2018-09-28
EP3359162A1 (en) 2018-08-15
MX2018004286A (es) 2018-08-09
AU2016335767A1 (en) 2018-05-24
IL258509A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
EP3426250A4 (en) TREATMENT PROCEDURE
EP3601536A4 (en) TREATMENT PROCEDURES
EP3303413A4 (en) PROCESS FOR THE PREPARATION OF SUGAMMADEX AND INTERMEDIATE PRODUCTS THEREOF
EP3377068A4 (en) COMBINATION THERAPY OF TETRACYCLIC CHINOLONANALOGES FOR THE TREATMENT OF CANCER
EP3388004A4 (en) Treatment instrument
EP3331527A4 (en) METHOD FOR TREATING DEVELOPMENT DISORDERS WITH PIPRADROL
EP3374502A4 (en) METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
MA43872A (fr) Procédé de traitement d'une glomérulopathie à c3
EP3398960A4 (en) METHOD FOR PRODUCING SERMAGLUTIDE
EP3500289A4 (en) METHOD FOR TREATING TRACHEOBRONCHOMALACY
EP3351189A4 (en) ENDOSCOPE TREATMENT INSTRUMENT
EP3515857A4 (en) UNIVERSAL DISPENSER MONITOR
EP3351188A4 (en) ENDOSCOPE TREATMENT INSTRUMENT
EP3421503A4 (en) SUGAMMADEX MANUFACTURE AND CLEANING PROCEDURE
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
EP3351186A4 (en) ENDOSCOPE TREATMENT INSTRUMENT
EP3341391A4 (en) COMPOSITIONS AND METHODS OF PAIN TREATMENT
EP3351187A4 (en) ENDOSCOPE TREATMENT INSTRUMENT
EP3409744A4 (en) SURFACE TREATMENT AGENT
EP3431566A4 (en) SURFACE TREATMENT AGENT
EP3328374A4 (en) GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
EP3455188C0 (de) Verfahren zur behandlung von schlacke
EP3326559A4 (en) ULTRASONIC TREATMENT TOOL AND ULTRASOUND TREATMENT ASSEMBLY
EP3334432A4 (en) CERDULATINIB FOR THE TREATMENT OF MYELOMA
EP3439657A4 (en) METHOD FOR TREATING DEVELOPMENT DISTURBANCES USING PIPRADROL